Surgery doesn't up pediatric neuroblastoma outcomes

Surgery doesn't up pediatric neuroblastoma outcomes
For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes, according to a study published online Jan. 2 in the Journal of Clinical Oncology.

(HealthDay)—For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes, according to a study published online Jan. 2 in the Journal of Clinical Oncology.

Thorsten Simon, M.D., from the University of Cologne in Germany, and colleagues reviewed operation notes and imaging reports from 278 patients with stage 4 neuroblastoma (age 18 months or older at diagnosis) participating in a prospective clinical trial.

The researchers found that at diagnosis there were image-defined risk factors that were significantly predictive for the extent of at first and best operation. Before chemotherapy, 6.1 percent of participants underwent complete resection, 5.0 percent underwent incomplete resection, and 88.5 percent underwent biopsy or no surgery. Following , 54.7, 30.6, and 13.3 percent underwent complete resection, incomplete resection, and only biopsy or no surgery of the primary tumor, respectively. The extent of first or best operation had no effect on event-free survival, local progression-free survival, or overall survival.

"In conclusion, the results of this study do not justify aggressive surgery in patients undergoing high-intensity multimodal treatment for metastatic neuroblastoma," the authors write. "Future trials are required to determine whether even less surgery might be adequate in high-intensity multimodal treatment of metastatic neuroblastoma and if biologic factors are correlated with the respectability of the primary tumor."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

High survival with surgery in low-risk neuroblastoma

Apr 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online ...

Gender, BMI impact bladder perforation during resection

Apr 17, 2012

(HealthDay) -- For patients with bladder tumors, female gender, low body mass index, and tumor characteristics correlate with the risk of bladder perforation during transurethral resection, according to research ...

Surgery not necessary for most late-stage colorectal cancers

May 31, 2009

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon. Researchers ...

Nonoperative approach feasible in advanced colon cancer

Aug 09, 2012

(HealthDay) -- Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) ...

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

12 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

16 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments